Tufts Center study shows significant time savings in delivering therapies to patients with Thermo Fisher Scientific’s Accelerator Drug Development 360° CDMO and CRO solutions
New research shows integrated services can reduce Phase I-III study times by up to nearly three years, generating strong ROI for biotech and biopharma customers